Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18957253 | 1.00 | PARP1 (0.32) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL17337169 | 0.92 | NAMPT (0.38) | PARP1NAMPTMAPT | |
| SCHEMBL17337165 | 0.92 | NAMPT (0.38) | PARP1NAMPTMAPT | |
| SCHEMBL17337295 | 0.91 | PARP1 (0.31) | PARP1MTNR1AMTNR1B | |
| SCHEMBL17337292 | 0.91 | PARP1 (0.31) | PARP1MTNR1AMTNR1B | |
| SCHEMBL22667280 | 0.91 | PARP1 (0.31) | PARP1MTNR1AMTNR1B | |
| SCHEMBL18957145 | 0.91 | PARP1 (0.32) | PARP1 | |
| SCHEMBL18957148 | 0.91 | PARP1 (0.32) | PARP1 | |
| SCHEMBL18957153 | 0.91 | NAMPT (0.38) | PARP1NAMPTMAPT | |
| SCHEMBL18966560 | 0.90 | PARP1 (0.31) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-11 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | PARP1 589/4885PDK1 2130/4885PDK2 2154/4885 |
| US-20180291039-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | PARP1 589/4885PDK1 2130/4885PDK2 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.